isoxazoles has been researched along with pi103 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deckert, S; Djuzenova, CS; Fiedler, V; Flentje, M; Katzer, A; Michel, K; Sukhorukov, VL; Zimmermann, H | 1 |
| Becker, N; Djuzenova, CS; Eing, L; Ferreira, FLR; Fiedler, V; Flentje, M; Heiden, R; Katzer, A; Memmel, S; Sauer, M; Sisario, D; Sukhorukov, VL; Zimmermann, H; Zöller, C | 1 |
2 other study(ies) available for isoxazoles and pi103
| Article | Year |
|---|---|
Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Administration Schedule; Drug Synergism; Furans; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols; TOR Serine-Threonine Kinases; Up-Regulation | 2016 |
Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities.
Topics: Actin Cytoskeleton; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cytoskeleton; Furans; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Resorcinols; TOR Serine-Threonine Kinases | 2017 |